The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Rivastigmine Sandoz

Sandoz Pharmaceuticals GmbHEU/1/09/599/13-16

Main Information

Trade NameRivastigmine Sandoz
Active SubstancesSdz ena 713 hta (rivastigmine hydrogen tartrate)
Dosage FormCapsule, hard
Licence HolderSandoz Pharmaceuticals GmbH
Licence NumberEU/1/09/599/13-16

Group Information

ATC CodeN06DA Anticholinesterases
N06DA03 rivastigmine


License statusAuthorised
Licence Issued
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal roduct subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2)
Marketing Status


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back